FCX vs HALO · P/E 38, rev $13.26B vs P/E 15, rev $857.7M
Freeport-McMoran Copper & Gold Inc (FCX) versus Halozyme Therapeutics Inc (HALO) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Not investment advice. Open the FCX and HALO stock pages for the full models.
Not investment advice.